Cargando…
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). T...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584583/ https://www.ncbi.nlm.nih.gov/pubmed/31218454 http://dx.doi.org/10.1186/s41687-019-0123-4 |
_version_ | 1783428538710360064 |
---|---|
author | Bell, Jill A. Galaznik, Aaron Pompilus, Farrah Strzok, Sara Bejar, Rafael Scipione, Fatima Fram, Robert J. Faller, Douglas V. Cano, Stefan Marquis, Patrick |
author_facet | Bell, Jill A. Galaznik, Aaron Pompilus, Farrah Strzok, Sara Bejar, Rafael Scipione, Fatima Fram, Robert J. Faller, Douglas V. Cano, Stefan Marquis, Patrick |
author_sort | Bell, Jill A. |
collection | PubMed |
description | BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument’s ability to detect clinically meaningful treatment benefit for this context of use. METHODS: Our mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30. RESULTS: Unique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact) were selected for the MDS/AML/CMML context. CONCLUSION: Supplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning. |
format | Online Article Text |
id | pubmed-6584583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-65845832019-07-05 A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia Bell, Jill A. Galaznik, Aaron Pompilus, Farrah Strzok, Sara Bejar, Rafael Scipione, Fatima Fram, Robert J. Faller, Douglas V. Cano, Stefan Marquis, Patrick J Patient Rep Outcomes Research BACKGROUND: Novel, pragmatic, patient-centered strategies are needed to ensure fit-for-purpose patient-reported outcomes (PRO) instruments in clinical trial research for rare diseases such as myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML). The objective of the current study was to select supplemental items to add to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) to ensure content coverage of all important clinical concepts in patients with higher-risk (HR) MDS, low-blast count (LB) AML, and CMML, thus, improving the instrument’s ability to detect clinically meaningful treatment benefit for this context of use. METHODS: Our mixed methods approach comprised literature review, clinician consultation (n = 3), and qualitative and quantitative analysis of two stages of patient interview data (n = 14, n = 18) to select library bank items to supplement a generic cancer PRO, the EORTC QLQ-C30. RESULTS: Unique symptom (n = 54) and impact (n = 72) concepts were organized into conceptual frameworks of treatment benefit, compared with EORTC QLQ-C30 items and conceptual gaps identified. Supplemental items (n = 13) addressing those gaps were selected from the EORTC Item Library and tested with patients. Supplemental item endorsement frequencies met World Health Organization Quality of Life criteria, suggesting good targeting and relevance for this sample. However, three supplemental items were confirmed as problematic based upon cognitive debriefing results, and expert clinical consultations. Ultimately, 10 supplemental items (n = 7 symptom; n = 3 impact) were selected for the MDS/AML/CMML context. CONCLUSION: Supplemental items were selected to enhance the conceptual coverage of the EORTC QLQ-C30 in the areas of fatigue, shortness of breath, and functioning. Springer International Publishing 2019-06-19 /pmc/articles/PMC6584583/ /pubmed/31218454 http://dx.doi.org/10.1186/s41687-019-0123-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Bell, Jill A. Galaznik, Aaron Pompilus, Farrah Strzok, Sara Bejar, Rafael Scipione, Fatima Fram, Robert J. Faller, Douglas V. Cano, Stefan Marquis, Patrick A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title_full | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title_fullStr | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title_full_unstemmed | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title_short | A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
title_sort | pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the eortc item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584583/ https://www.ncbi.nlm.nih.gov/pubmed/31218454 http://dx.doi.org/10.1186/s41687-019-0123-4 |
work_keys_str_mv | AT belljilla apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT galaznikaaron apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT pompilusfarrah apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT strzoksara apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT bejarrafael apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT scipionefatima apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT framrobertj apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT fallerdouglasv apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT canostefan apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT marquispatrick apragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT belljilla pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT galaznikaaron pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT pompilusfarrah pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT strzoksara pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT bejarrafael pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT scipionefatima pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT framrobertj pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT fallerdouglasv pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT canostefan pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia AT marquispatrick pragmaticpatientreportedoutcomestrategyforrarediseaseclinicaltrialsapplicationoftheeortcitemlibrarytomyelodysplasticsyndromeschronicmyelomonocyticleukemiaandacutemyeloidleukemia |